
Lars-Olof Wahlund

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7136083/publications.pdf Version: 2024-02-01



LARS-OLOF WAHLUND

#	Article	IF	CITATIONS
1	The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 264.	3.4	322
2	Cerebrospinal fluid A?42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Annals of Neurology, 1999, 45, 504-511.	5.3	224
3	AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 36-46.	3.8	193
4	Decreased α-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's diseas. Nature Medicine, 1995, 1, 829-832.	30.7	163
5	White matter changes and late-life depressive symptoms. British Journal of Psychiatry, 2007, 191, 212-217.	2.8	141
6	Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Scientific Reports, 2017, 7, 46263.	3.3	141
7	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
8	The AddNeuroMed framework for multiâ€centre MRI assessment of Alzheimer's disease : experience from the first 24 months. International Journal of Geriatric Psychiatry, 2011, 26, 75-82.	2.7	127
9	MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. Annals of the New York Academy of Sciences, 2009, 1180, 47-55.	3.8	121
10	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage, 2011, 58, 818-828.	4.2	121
11	Global Burden of Small Vessel Disease–Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke, 2020, 51, 170-178.	2.0	115
12	Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease. Cerebral Cortex, 2016, 26, 3476-3493.	2.9	110
13	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	3.1	110
14	Meta-Review of CSF Core Biomarkers in Alzheimerââ,¬â"¢s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Frontiers in Aging Neuroscience, 2014, 6, 47.	3.4	105
15	Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease. PLoS ONE, 2011, 6, e22506.	2.5	103
16	Default Mode Network Complexity and Cognitive Decline in Mild Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 770.	2.8	103
17	EEG Theta Power Is an Early Marker of Cognitive Decline in Dementia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 1359-1371.	2.6	100
18	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. Human Brain Mapping, 2015, 36, 2980-2995.	3.6	87

#	Article	IF	CITATIONS
19	Plasma Fatty Acid Profiles in Relation toÂCognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 FattyÂAcid Supplementation: The OmegADÂStudy. Journal of Alzheimer's Disease, 2015, 48, 805-812.	2.6	82
20	Brain Changes in Alzheimer's Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor. Journal of Alzheimer's Disease, 2014, 43, 1059-1072.	2.6	71
21	The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice. Neurobiology of Aging, 2016, 37, 47-57.	3.1	70
22	Mild cognitive impairment: experience from a memory clinic. Acta Neurologica Scandinavica, 2003, 107, 21-24.	2.1	69
23	Vitamin D in Relation to Cognitive Impairment, Cerebrospinal Fluid Biomarkers, and Brain Volumes. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 1132-1138.	3.6	68
24	Sex differences in volume and structural covariance of the anterior and posterior hippocampus. NeuroImage, 2014, 99, 215-225.	4.2	68
25	Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Into Imaging, 2017, 8, 79-90.	3.4	67
26	Myo-inositol changes precede amyloid pathology and relate to <i>APOE</i> genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761.	1.1	66
27	27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. Journal of Experimental Medicine, 2017, 214, 699-717.	8.5	64
28	Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. Medical Physics, 2001, 28, 1660-1668.	3.0	62
29	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer's and Dementia, 2019, 15, 400-409.	0.8	60
30	Head-to-Head Comparison of Two Popular Cortical Thickness Extraction Algorithms: A Cross-Sectional and Longitudinal Study. PLoS ONE, 2015, 10, e0117692.	2.5	53
31	Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. International Journal of Geriatric Psychiatry, 2015, 30, 744-750.	2.7	51
32	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	3.1	51
33	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1316-1328.	0.8	50
34	MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?. American Journal of Neuroradiology, 2017, 38, 1737-1741.	2.4	50
35	Cognitive decline is mediated by gray matter changes during middle age. Neurobiology of Aging, 2014, 35, 1086-1094.	3.1	48
36	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. Neurobiology of Aging, 2018, 70, 18-29.	3.1	48

Lars-Olof Wahlund

#	Article	IF	CITATIONS
37	Investigations of a CA repeat in the oestrogen receptor \hat{I}^2 gene in patients with Alzheimer's disease. European Journal of Human Genetics, 2001, 9, 802-804.	2.8	46
38	DHA-rich n–3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study. American Journal of Clinical Nutrition, 2017, 106, 1157-1165.	4.7	46
39	Perivascular Spaces in Old Age: Assessment, Distribution, and Correlation with White Matter Hyperintensities. American Journal of Neuroradiology, 2018, 39, 70-76.	2.4	45
40	Improving CSF Biomarkersââ,¬â,,¢ Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimerââ,¬â,,¢s Disease by Considering Different Confounding Factors: A Meta-Analysis. Frontiers in Aging Neuroscience, 2014, 6, 287.	3.4	44
41	Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors. Journal of Alzheimer's Disease, 2016, 55, 625-644.	2.6	44
42	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	1.8	44
43	Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: A populationâ€based study. Alzheimer's and Dementia, 2017, 13, 247-256.	0.8	42
44	<i>APOE</i> and cortical superficial siderosis in CAA. Neurology, 2019, 93, e358-e371.	1.1	42
45	The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study. Alzheimer's Research and Therapy, 2020, 12, 51.	6.2	41
46	The heterogeneity within Alzheimer's disease. Aging, 2018, 10, 3058-3060.	3.1	41
47	Evidence-based Evaluation of Magnetic Resonance Imaging as a Diagnostic Tool in Dementia Workup. Topics in Magnetic Resonance Imaging, 2005, 16, 427-437.	1.2	40
48	APOE ε2 Allele Is Associated with Larger Regional Cortical Thicknesses and Volumes. Dementia and Geriatric Cognitive Disorders, 2010, 30, 229-237.	1.5	40
49	Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 621-628.	4.3	40
50	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	4.5	39
51	Discovering EEG resting state alterations of semantic dementia. Clinical Neurophysiology, 2016, 127, 2175-2181.	1.5	38
52	Cortical superficial siderosis. Neurology, 2016, 87, 1110-1117.	1.1	37
53	Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. Acta Radiologica, 2012, 53, 318-323.	1.1	35
54	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. Alzheimer's Research and Therapy, 2014, 6, 41.	6.2	33

Lars-Olof Wahlund

#	Article	IF	CITATIONS
55	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	2.6	33
56	Comparison between visual assessment of MTA and hippocampal volumes in an elderly, non-demented population. Acta Radiologica, 2012, 53, 573-579.	1.1	32
57	Predicting Fazekas scores from automatic segmentations of white matter signal abnormalities. Aging, 2020, 12, 894-901.	3.1	32
58	Oscillatory connectivity as a diagnostic marker of dementia due to Alzheimer's disease. Clinical Neurophysiology, 2019, 130, 1889-1899.	1.5	30
59	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.1	30
60	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Frontiers in Aging Neuroscience, 2014, 6, 145.	3.4	29
61	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	2.6	27
62	Galantamine Versus Risperidone Treatment of Neuropsychiatric Symptoms in Patients with Probable Dementia: An Open Randomized Trial. American Journal of Geriatric Psychiatry, 2014, 22, 341-348.	1.2	26
63	Cerebral microbleeds as a biomarker in Alzheimer's disease? A review in the field. Biomarkers in Medicine, 2016, 10, 9-18.	1.4	26
64	Androgen deprivation therapy for prostate cancer and risk of dementia. BJU International, 2019, 124, 87-92.	2.5	26
65	The Power of EEG to Predict Conversion from Mild Cognitive Impairment and Subjective Cognitive Decline to Dementia. Dementia and Geriatric Cognitive Disorders, 2020, 49, 38-47.	1.5	25
66	Cerebral microbleeds topography and cerebrospinal fluid biomarkers in cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1006-1013.	4.3	24
67	Functional Connectivity Alterations of the Temporal Lobe and Hippocampus in Semantic Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 1461-1475.	2.6	24
68	Atrial Fibrillation, Stroke, and Silent Cerebrovascular Disease. Neurology, 2021, 97, e1608-e1619.	1.1	24
69	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. NeuroImage: Clinical, 2017, 16, 418-428.	2.7	23
70	Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2015, 28, 40-48.	2.3	22
71	Changes in the left temporal microstate are a sign of cognitive decline in patients with Alzheimer's disease. Brain and Behavior, 2020, 10, e01630.	2.2	22
72	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	3.4	21

LARS-OLOF WAHLUND

#	Article	IF	CITATIONS
73	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	1.9	20
74	AVRA: Automatic visual ratings of atrophy from MRI images using recurrent convolutional neural networks. Neurolmage: Clinical, 2019, 23, 101872.	2.7	20
75	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease. Journal of the International Neuropsychological Society, 2017, 23, 195-203.	1.8	18
76	Shape Analysis of the Corpus Callosum in Alzheimer's Disease and Frontotemporal Lobar Degeneration Subtypes. Journal of Alzheimer's Disease, 2014, 40, 897-906.	2.6	17
77	Automated CT-based segmentation and quantification of total intracranial volume. European Radiology, 2015, 25, 3151-3160.	4.5	17
78	Shape Abnormalities of the Caudate Nucleus Correlate with Poorer Gait and Balance: Results from a Subset of the LADIS Study. American Journal of Geriatric Psychiatry, 2015, 23, 59-71.e1.	1.2	16
79	Apolipoprotein E ϵ4 is positively related to spatial performance but unrelated to hippocampal volume in healthy young adults. Behavioural Brain Research, 2016, 299, 11-18.	2.2	14
80	Deep learning from MRI-derived labels enables automatic brain tissue classification on human brain CT. NeuroImage, 2021, 244, 118606.	4.2	13
81	The protective gene dose effect of the <i>APOEε2</i> allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.8	13
82	The neural correlates of self-paced finger tapping in bipolar depression with motor retardation. Acta Neuropsychiatrica, 2013, 25, 43-51.	2.1	12
83	Specific patterns of whole-brain structural covariance of the anterior and posterior hippocampus in young APOE ε4 carriers. Behavioural Brain Research, 2017, 326, 256-264.	2.2	12
84	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial—The OmegAD Study. Journal of Alzheimer's Disease, 2021, 83, 1291-1301.	2.6	10
85	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimer's Research and Therapy, 2022, 14, 14.	6.2	10
86	Mild cognitive impairment: experience from a memory clinic. Acta Neurologica Scandinavica, Supplement, 2003, 179, 21-4.	0.7	10
87	Diverging Progression of Network Disruption and Atrophy in Alzheimer's Disease and Semantic Dementia. Journal of Alzheimer's Disease, 2016, 55, 981-993.	2.6	9
88	Structural brain imaging as a diagnostic tool in dementia, why and how?. Psychiatry Research - Neuroimaging, 2020, 306, 111183.	1.8	9
89	Cerebrospinal Fluid Metals and the Association with Cerebral Small Vessel Disease. Journal of Alzheimer's Disease, 2020, 78, 1229-1236.	2.6	9
90	Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases. Psychiatry Research - Neuroimaging, 2020, 302, 111099.	1.8	9

LARS-OLOF WAHLUND

#	Article	IF	CITATIONS
91	The Effects of Gene Mutations onÂDefaultÂMode Network inÂFamilialÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 327-334.	2.6	8
92	Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. Neuroradiology, 2020, 62, 1257-1263.	2.2	8
93	Kinetic aspects of monoamine oxidase activity in twins with psychoses. Clinical Genetics, 1981, 19, 395-400.	2.0	7
94	Effects of amyloid pathology and the APOE Îμ4 allele on the association between cerebrospinal fluid Aβ38 and Aβ40 and brain morphology in cognitively normal 70-years-olds. Neurobiology of Aging, 2021, 101, 1-12.	3.1	7
95	Activation of monoamine oxidase by high molecular weight fractions of human plasma. Acta Physiologica Scandinavica, 1984, 120, 337-341.	2.2	6
96	The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment. BMC Geriatrics, 2020, 20, 93.	2.7	6
97	Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination. Journal of Alzheimer's Disease Reports, 2021, 5, 1-19.	2.2	6
98	Brain Atrophy Subtypes and the ATN Classification Scheme in Alzheimer's Disease. Neurodegenerative Diseases, 2020, 20, 153-164.	1.4	6
99	Physical activity level in people with age related white matter changes correlates to better motor performance, lower comorbidity and higher cognitive level. BMC Geriatrics, 2017, 17, 142.	2.7	5
100	The Australian, US, Scandinavian Imaging Exchange (AUSSIE): an innovative, virtually-integrated health research network embedded in health care. Australasian Psychiatry, 2014, 22, 260-265.	0.7	4
101	Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults. Frontiers in Aging Neuroscience, 2021, 13, 777475.	3.4	4
102	Activity of platelet monoamine oxidase in apparently healthy subjects. Clinical Genetics, 1981, 19, 400-405.	2.0	3
103	Platelet monoamine oxidase activity in schlzophrenic familiesâ€kinetic aspects. Clinical Genetics, 1981, 19, 405-409.	2.0	3
104	Does Fatty Acid Composition in Subcutaneous Adipose Tissue Differ between Patients with Alzheimer's Disease and Cohabiting Proxies?. Journal of Alzheimer's Disease, 2017, 61, 515-519.	2.6	2
105	Cognitive dedifferentiation as a function of cognitive impairment in the ADNI and MemClin cohorts. Aging, 2021, 13, 13430-13442.	3.1	2
106	P2â€⊋70: Longitudinal Investigation of an MRIâ€Based Alzheimer's Disease Diagnostic Index in Adni. Alzheimer's and Dementia, 2016, 12, P732.	0.8	1
107	IC-P-120: PREVALENCE, TOPOGRAPHY, AND RISK FACTORS OF CEREBRAL MICROBLEEDS IN DEMENTIA. , 2014, 10, P67-P68.		0
108	Response to Bogaiksy's Letter to the Editor. American Journal of Geriatric Psychiatry, 2014, 22, 951.	1.2	0

7

#	Article	IF	CITATIONS
109	P3-180: DISTINCT NEURAL SIGNATURES OF DIFFERENT APOE GENE POLYMORPHISMS ON HIPPOCAMPAL VOLUME: A LARGE SCALE STUDY IN ALZHEIMER'S DISEASE AND NORMAL HEALTHY AGEING. , 2014, 10, P694-P694.		0
110	O5-02-01: PREVALENCE, TOPOGRAPHY, AND RISK FACTORS OF CEREBRAL MICROBLEEDS IN DEMENTIA. , 2014, 10, P290-P291.		0
111	IC-P-092: A LONGITUDINAL STUDY OF AN MRI BASED SEVERITY INDEX IN THE ADDNEUROMED COHORT. , 2014, 10, P52-P52.		0
112	P1-020: Structural brain changes mediate the association between cardiovascular risk burden and cognitive decline in old age: A population-based study. , 2015, 11, P344-P344.		0
113	O1-04-05: Hypertension, APOE-ɛ4 allele, regional white-matter hyperintensities, and cognitive decline in old age: A population-based study. , 2015, 11, P134-P134.		0
114	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
115	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0
116	[ICâ€Pâ€123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AN PATHOLOGY IN NONâ€DEMENTED INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P94.	D AÎ ² 0.8	0
117	[P2–194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.8	0
118	Editorial. Psychiatry Research - Neuroimaging, 2020, 306, 111175.	1.8	0
119	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia, 2020, 16, e038588.	0.8	0
120	Atrial fibrillation and the interaction with stroke in relation to white matter lesion volumes: A populationâ€based study in 70â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e043296.	0.8	0
121	The Use of Magnetic Resonance Imaging Techniques in Assessing the Effects of Alcohol Consumption and Heavy Drinking on the Adolescent Brain: A Scoping Review Protocol. Brain Sciences, 2021, 11, 764.	2.3	0
122	Nâ€3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal, 2009, 23, 543.10.	0.5	0
123	Demographic and Clinical Characteristics of Individuals with Mild Cognitive Impairment Related to Grade of Alcohol Consumption. Dementia and Geriatric Cognitive Disorders, 2021, 50, 491-497.	1.5	0
124	The association of Alzheimer's disease and cerebrovascular disease biomarkers towards the neurodegeneration of the cholinergic pathways. Alzheimer's and Dementia, 2021, 17, .	0.8	0
125	Association of deepâ€learning–derived brain computed tomography measures with cognition and bloodâ€based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, .	0.8	Ο